Obesity and type-2 diabetes have increased markedly over the past few decades, in parallel. One of the major links between these two disorders is chronic, low-grade inflammation 1 . Prolonged nutrient excess promotes the accumulation and activation of leukocytes in visceral adipose tissue (VAT) and ultimately other tissues, leading to metabolic abnormalities such as insulin resistance, type-2 diabetes and fatty-liver disease. Although invasion of VAT by proinflammatory macrophages is considered to be a key event driving adipose-tissue inflammation and insulin resistance, little is known about the roles of other immune system cell types in these processes. A unique population of VAT-resident regulatory T (T reg ) cells was recently implicated in control of the inflammatory state of adipose tissue and, thereby, insulin sensitivity 2 . Here we identify peroxisome proliferator-activated receptor (PPAR)-c, the 'master regulator' of adipocyte differentiation, as a crucial molecular orchestrator of VAT T reg cell accumulation, phenotype and function. Unexpectedly, PPAR-c expression by VAT T reg cells was necessary for complete restoration of insulin sensitivity in obese mice by the thiazolidinedione drug pioglitazone. These findings suggest a previously unknown cellular mechanism for this important class of thiazolidinedione drugs, and provide proof-ofprinciple that discrete populations of T reg cells with unique functions can be precisely targeted to therapeutic ends.
A unique population of Foxp3 1 CD4 1 T reg cells was recently found in the VAT of normal individuals 2 , at a much higher fraction of the CD4 1 T-cell compartment than that usually observed in lymphoid or other non-lymphoid tissues. VAT T reg cells had a readily distinguishable phenotype from that of their counterparts in the spleen and lymph nodes, including a distinct gene expression profile, T-cell receptor repertoire, and pattern of chemokine and chemokine receptor expression. Adipose tissue inflammation and both local and systemic metabolic indices were improved or worsened by global enrichment or impoverishment, respectively, of T reg cells [2] [3] [4] . However, a lack of appropriate reagents has so far precluded an assessment of the precise role of fat-resident T reg cells.
The molecules that orchestrate the distinctive properties of VAT T reg cells are unknown. Comparing the gene expression profiles of mouse visceral fat and lymphoid organ T reg cells, we were struck by the increased level of transcripts encoding the nuclear receptor PPARc in the former ( Fig. 1a and Supplementary Fig. 1a ). The specificity of this increase was highlighted by a comparison of Pparg transcript levels across a large library of microarray data sets (more than 350) encompassing T cells of diverse subsets, activation statuses and localizations ( Fig. 1b ). Because of the crucial role of PPAR-c in adipocyte differentiation, as well as its anti-inflammatory activities 5 , we speculated that its expression in VAT T reg cells might be responsible for at least some of their unique features.
To identify genes that were positively or negatively correlated with Pparg expression, we performed a clustering analysis across transcript profiles obtained from VAT and lymph node T reg cells of mice differing in their metabolic state: either lean (C57Bl/6 (B6) animals of various ages kept on normal chow) or obese (B6.Lep ob/ob (ob/ob) animals of varying age on normal chow or B6 animals on a high-fat diet (HFD)) ( Supplementary Fig. 1b, c) . The set of loci whose expression was co-or anti-correlated with Pparg transcript levels encompassed the majority of those most strongly up-(red) or down-(blue) regulated, respectively, in visceral fat versus lymphoid tissue T reg cells 2 (Fig. 1c ). The coclustered transcripts included many that encode chemokines or chemokine receptors involved in leukocyte migration and extravasation (for example, Ccr1, Ccr3, Cxcr6, Cxcl2 and Cxcl3), several encoding molecules involved in lipid metabolism (Pcyt1a and Dgat1), and Il10 transcripts. We directly evaluated the role of PPAR-c in specifying the VAT T reg cell phenotype by retrovirally transducing Foxp3 alone or together with Pparg into naive CD4 1 T cells activated in vitro with anti-CD3/CD28-coated beads (neither transcription factor being expressed at detectable levels in the host CD4 1 T cells). Two isoforms of PPAR-c have been described, referred to as PPAR-c1 and PPAR-c2 (ref. 5); although adipocytes are known to express both of them, the isoform(s) made by T lymphocytes is not well characterized. Feature-level analysis of Pparg transcripts, exploiting our existing Affymetrix ST 1.0 microarray data, showed that messenger RNAs corresponding to both PPAR-c1 and PPAR-c2 were expressed by VAT T reg cells, with predominance of the former ( Supplementary Fig. 2a ), whereas the lowlevel transcripts made by the other T-cell populations primarily encoded PPAR-c2 (not shown). Therefore, we evaluated the ability of each isoform to cooperate with Foxp3 to promote the VAT T reg cell gene expression signature. Most transcripts are distributed in a grey cloud along the diagonal in the fold-change/fold-change (FC/FC) plot of Fig. 2a , showing that Pparg1 and Pparg2 induced the expression of a similar set of genes when co-transduced with Foxp3; the slight tilt towards the x-axis indicates that Pparg1 transduction was slightly more potent. Each isoform promoted expression of the abovediscussed Pparg co-cluster (red cloud along the diagonal), although only Pparg1 repressed expression of the bulk of the Pparg anti-cluster (blue cloud along the x-axis). Similarly, as illustrated most clearly by the Pparg plus Foxp3 versus Foxp3 alone 'volcano plots' (Fig. 2b, c) , each PPAR-c isoform could collaborate with Foxp3 to upregulate a substantial fraction of the genes characteristic of the VAT T reg cell upsignature (pink, skewed to the right in Fig. 2b, c) . However, the corresponding down-signature was partially recapitulated only after Pparg1 plus Foxp3 transduction (green, skewed to the left in Fig. 2c but not in Fig. 2d ).
Because adequate PPAR-c ligand might not be available in this in vitro context, we explored the effect of adding a synthetic agonist, the thiazolidinedione (TZD) drug pioglitazone (Pio). Twenty-four hours after retroviral infection, double (Pparg1 plus Foxp3, or Pparg2 plus Foxp3) or single (Foxp3 alone) transductants were treated with Pio for 48 h. The most notable effect of this agonist, whether in the context of Pparg1 or Pparg2, was the augmentation of a set of 'lipid metabolism' genes, some of which were reported to be differentially expressed in VAT versus lymph node T reg cells in a previous ex vivo microarray analysis 2 . This influence was most obvious on FC/FC plots ( Fig. 2d, e ), which isolate the effect of Pio in the context of each isoform (as aligned towards the x-axis). Upregulated genes involved in lipid metabolism included those coding for fatty-acid transporters (Cd36 and Slc27a2), enzymes involved in fatty-acid synthesis (Lipe and Scd1), an enzyme essential for fatty-acid oxidation (Cpt1a), an enzyme responsible for the synthesis of triglycerides (Dgat1), and a lipiddroplet-associated protein (Plin2). Similar results were obtained with rosiglitazone, another TZD drug, or with GW1929, a potent non-TZD PPAR-c agonist ( Supplementary Fig. 2b , c; note change in axis labels compared with Fig. 2d, e ). The fact that PPAR-c could cooperate with Foxp3 to impose a VAT T reg cell phenotype on naive CD4 1 T cells raised the question of whether the two transcription factors interact in some way. Indeed, both PPAR-c isoforms were co-immunoprecipitated with Foxp3 in transduced HEK293 cells, arguing that they have the potential to interact, either directly or within a shared complex ( Fig. 2f ). (Unfortunately, we could not obtain adequate material from ex vivo T cells to perform an analogous experiment.)
To assess the importance of PPAR-c for the VAT T reg phenotype in vivo, we abrogated its expression specifically in T reg cells by crossing a mouse line carrying 'floxed' Pparg with a line expressing the Cre recombinase under the dictates of Foxp3 promoter/enhancer elements. The T reg cell specificity of Cre expression in such mice has been validated in several contexts. At 25 weeks, the resulting mutants had lower fractions and numbers of VAT T reg cells than their Pparg wild-type littermates (carrying the Foxp3-Cre transgene); by contrast, the representation of T reg cells in the lymphoid organs of mutants was normal ( Fig. 3a) . Although VAT T reg cells in wild-type mice increased .2.5-fold between 15 and 25 weeks to eventually constitute more than 40% of the CD4 1 T cell compartment, this subset remained below ,10% in the mutant mice ( Supplementary Fig. 3a ). The T reg cells remaining in the VAT (but not those in the spleen) of mutants had a lower mean fluorescence intensity (MFI) of Foxp3 expression than that of their wild-type counterparts ( Supplementary Fig. 3b ). A volcano plot comparing gene expression in VAT T reg cells from Pparg wildtype and mutant mice showed the VAT T reg cell up-signature (pink, skewed to the right) to be underrepresented in mutant T cells, whereas, conversely, the down-signature (green, skewed to the left) was overrepresented ( Fig. 3b ). VAT and lymphoid organ T reg cells were much more similar in the Pparg mutant than in the wild-type mice ( Supplementary Fig. 3c) ; this difference reflected alterations at the level IP : a n t i-P P A R -γ 1 + 2 IP : a n t i-Ig 
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of VAT T reg cells, as the absence of PPAR-c expression in lymph node T reg cells had little impact ( Supplementary Fig. 3d ). This observation was confirmed at the protein level ( Supplementary Fig. 4 ): downregulation of CCR2, GATA3, KLRG1 and CD69 in mutant versus wild-type VAT T reg cells to resemble the lower levels in lymphoid tissue T reg cells; upregulation of CD103 and CD86 in mutant VAT T reg cells to approach the higher levels in lymphoid T reg cells. Thus, PPAR-c is an important factor controlling the accumulation and phenotype of T reg cells residing in adipose tissue. How the loss of PPAR-c influences the turnover of T reg cells residing in VAT is unclear. Addressing this issue was more complex than simply comparing the half-life of VAT T reg cells in wild-type and mutant mice because the residual T reg cells in the latter animals are likely to be atypical 'survivors' and/or recruits from the lymphoid T reg cell pool exploiting a niche empty of the usual competitors. So we performed an acute assay, monitoring T reg cell populations in wildtype mice over a few days of treatment with the irreversible PPAR-c inhibitor GW9662 ( Supplementary Fig. 5a ). There were no significant differences in the VAT or spleen T reg cell fraction or numbers in the drug-versus vehicle-treated animals ( Supplementary Fig. 5b, c) . However, there was a progressive decline in the fraction of GATA3 1 T reg cells in VAT (but not in spleen), and a parallel decrease in the GATA3 MFI ( Supplementary Fig. 5d, e ). The GATA3 transcription factor is highly overrepresented in VAT versus lymphoid tissue T reg cells, and is downregulated in the absence of PPAR-c ( Supplementary  Fig. 4 ). Altogether, our data indicate that PPAR-c may control both the establishment and the maintenance of the VAT T reg cell phenotype.
Secondarily, the mutant mice had fractional and numerical increases in some, but not all, adipose tissue monocyte/macrophage subsets: pro-inflammatory CD11b 1 CD11c 1 F4/80 1 macrophages ( Supplementary Fig. 6a , c) and pro-inflammatory CD11b 1 Ly6c hi monocytes (left panels in Supplementary Fig. 6b, d ), but not CD11b 1 Ly6c low monocytes (right panels in Supplementary Fig. 6b,  d ), considered to be anti-inflammatory. There were no changes in the fractions or numbers of CD8 1 T or B cells in VAT of mutant mice ( Supplementary Fig. 6e-h) .
Pio is a well-known insulin-sensitizing agent that improves metabolic indices in obese mice and humans. Given its ability to enhance the unique fat T reg cell signature in cultured cells (Fig. 2d, e ), we wondered how this drug might affect VAT T reg cells in obese (HFDfed) mice. There was an impressive enrichment of the fraction and number of T reg cells in epididymal adipose tissue of animals treated with Pio ( Fig. 4a and Supplementary Fig. 7a ); this effect was specific, and not seen in the spleen, subcutaneous fat, perirenal fat or liver ( Fig. 4a and Supplementary Fig. 7b ). There were also marked phenotypic changes in the epididymal fat T reg cell population of Pio-treated and equivalent untreated obese mice: an overall shift of the gene expression profile towards that typical of VAT T reg cells (Fig. 4b) ; an increase in the Foxp3 MFI ( Supplementary Fig. 7c) ; a PPAR-cdependent enrichment of cells expressing GATA3 ( Supplementary  Fig. 7d ); and enhanced cell-surface display of the lipid scavenger CD36 (Fig. 4c) . As PPAR-c ligands are known to stimulate oxidized low-density lipoprotein uptake by augmenting levels of CD36 on the surface of macrophages 6 , we stained T reg cells with Nile red, a dye that selectively binds to intracellular lipid droplets. VAT, but not spleen, T reg cells readily took up lipids, especially in response to Pio (Fig. 4d ). This process was PPAR-c-dependent as the Pio-induced increase in CD36 expression and Nile red staining were both greatly dampened in Pparg mutant mice ( Supplementary Fig. 7e, f) . Thus, Pio accentuates the accumulation and phenotype of fat T reg cells in epididymal fat depots of obese mice.
The marked increase in the representation of and alterations in the phenotype of VAT T reg cells provoked by Pio treatment of obese mice raised the question of whether this population contributes to the insulin-sensitizing effect of Pio. In analogy to the human context, we compared immunological and metabolic parameters in obese (HFDfed) Pparg wild-type and mutant mice as a function of Pio cotreatment. As anticipated, the VAT T reg cell population of wild-type animals fed a HFD was quite low, and it increased substantially when Pio was included in the diet (Fig. 4e) . Also as expected, the representation of VAT T reg cells in mutant animals on a HFD was similar to that of their wild-type counterparts: a HFD in and of itself results in death and/or evacuation of typical VAT T reg cells, so abrogation of PPAR-c expression in this context has no further effect. Pio could not expand VAT T reg cells in the mutant (Fig. 4e ). Pio had differential effects on conventional adipose tissue monocyte/macrophage populations in HFD-fed mutant mice: pro-inflammatory macrophages (CD11b 1 CD11c 1 F4/80 1 ) were diminished, although not to the degree seen in wild-type littermates ( Supplementary Fig. 8a) ; by contrast, proinflammatory monocytes (CD11b 1 Ly6c hi ) did not undergo their usual reduction ( Supplementary Fig. 8b, left) ; whereas anti-inflammatory monocytes (CD11b 1 Ly6c low ) uncharacteristically declined ( Supplementary Fig. 8b, right) . Pio treatment of obese mutant mice was less effective than the treatment of their wild-type counterparts at normalizing systemic metabolic parameters: homeostatic model assessment of insulin resistance (Fig. 4f ), glucose and insulin tolerance LETTER RESEARCH ( Fig. 4g and Supplementary Fig. 8c ), and phosphorylated (p)AKT levels in multiple organs ( Supplementary Fig. 8d ). At least some of the muted metabolic response to Pio reflected events in VAT, evidenced by the lack of normalization of pAKT values at that site. The Pio treatment clearly worked, however, as we observed in both wild-type and mutant drug-treated HFD-fed mice the expected increase in epididymal fat-pad weight ( Supplementary Fig. 9a ), although not in total body weight (not shown); a coupled decrease in adipocyte numbers and an increase in adipocyte size (Supplementary Fig. 9b, c) ; and increased levels of serum adiponectin and Adipoq transcripts ( Supplementary Fig. 9d ). Leptin (Lep) transcript levels were unchanged in both wild-type and HFD-fed individuals (Supplementary Fig. 9e) , as anticipated 7 . The main conclusion from our results is that PPAR-c is a major orchestrator of the unique properties of VAT T reg cells. This nuclear receptor collaborates with Foxp3 to impose on naive CD4 1 T cells the transcriptional profile characteristic of VAT T reg cells. Interestingly, both PPAR-c isoforms can promote the fat T reg up-signature in conjunction with Foxp3, but only isoform 1 drives the down-signature. This constitutes a rare dysjunction in the activities of the two PPAR-c isoforms, which differ by only an extra 30 amino acids at the amino terminus of PPAR-c2. Experimental manipulation of PPAR-c specifically in Foxp3 1 cells had a clear and precise impact on the accumulation and phenotype of T reg cells in epididymal fat depots. A newly discovered property was that VAT, but not lymphoid tissue, T reg cells can take up lipids, an intriguing adaptation to the tissular environment, not shared by conventional T cells residing at the same site. It remains to be determined whether this feature promotes T reg cell survival or effector functions, or whether it is an epiphenomenon.
Our data also indicate that PPAR-c expressed by T reg cells contributes substantially to the insulin-sensitizing activity of Pio. It was initially assumed, given the role of this transcription factor in fat-cell differentiation, that TZD drugs improve metabolic parameters in obese individuals by activating PPAR-c in adipocytes. Although this notion has received experimental support 8 , other studies have argued for the importance of PPAR-c expression in macrophages 9,10 , muscle 11 and the central nervous system 12, 13 . On first consideration, it seems difficult to explain the need for PPAR-c across such a broad range of cell types, but several points should be kept in mind. First, TZD drugs may affect several processes upstream of insulin resistance, for example, ingestive behaviour, adipocity and inflammation; PPAR-cdriven programs in different cell types may influence these processes differentially. Second, abrogating PPAR-c expression in different cell types seems to have organ-specific effects on insulin resistance [11] [12] [13] . And third, there is increasing appreciation that the gene promoters used to generate transgenic mouse lines with cell-type-specific ablation of PPAR-c can be 'leaky'. Delineating the cell type(s) crucial for the protective effect of Pio on metabolic disorders is imperative given current concerns over the side effects of the TZD class of compounds and the resultant search for alternative drugs 14 . phenotype. At 9 weeks of age, wild-type and mutant Pparg mice (T reg -Pparg mut) were fed a HFD with or without Pio for 13 weeks. Cells from the spleen and epididymal fat SVF were stained and analysed by flow cytometry. Numbers on dot plots indicate the percentage of cells in that gate for that particular experiment (representative of at least three experiments). a, T reg cells from Pparg wild-type mice on a HFD with or without Pio. Left, representative dot plots; right, summary data. b, Expression of VAT T reg cell signature genes in Pparg wild-type mice on a HFD with or without Pio. Volcano plot compares P value versus fold-change for probes from VAT T reg cells isolated from Pparg wild-type mice on a HFD plus Pio versus a HFD alone. Genes from the VAT T reg up-and down-signature are highlighted in pink and green, respectively. P values from a chi-squared test. c, MFI of CD36 expression by T reg cells. DMFI indicates, for gated CD3 1 CD4 1 Foxp3 1 cells, the difference in CD36 expression for HFD-fed mice with or without Pio treatment. Epi-fat DMFI 5 3,828 6 1,362 (*P 5 0.039); spleen DMFI 5 2182 6 597 (NS). d, Cells were isolated from the spleen or epi-fat SVF of B6. Foxp3-(YFP-)Cre mice kept on a HFD with or without Pio for 13 weeks, and stained for CD3, CD4 and Nile red. YFP, yellow fluorescent protein. *P 5 0.01. e, T reg cell fraction. Cells from spleen or epi-fat SVF were stained and analysed by flow cytometry. f, Insulin sensitivity. Mice were assessed for blood fasting-glucose and fasting-insulin levels. These values were used to calculate the homeostatic model assessment of insulin resistance (HOMA-IR). g, Glucose tolerance. Left, intraperitoneal glucose tolerance test (GTT) on wild-type mice. Centre, GTT on mutant mice. Right, area under the curve (AUC) calculations. n 5 13-14 mice per group. *P , 0.05, ***P , 0.001 (Student's t-test). Error bars denote mean 6 s.d. for immunological parameters, mean 6 s.e.m. for metabolic parameters, as is standard practice in the respective fields.
Lastly, our results provide proof-of-principle that it is possible to target a designated population of T reg cells for a particular therapeutic goal. The emerging notion that the Foxp3 1 CD4 1 T reg cell compartment includes several subtypes with distinct phenotypes, localizations and effector functions 15 has evoked the exciting possibility of developing strategies to expand or contract disease-relevant T reg cells, leaving the bulk of the compartment intact to maintain immune homeostasis.
METHODS SUMMARY
Source and maintenance of mice are described in Methods. Experimentals and controls were always littermate-matched males (for example, Pparg fl/fl -FoxP3 YFP-Cre and Pparg wt -FoxP3 YFP-Cre ). HFD and normal-chow animals were fed a diet containing 60 kcal% and 10 kcal% fat, respectively. Mice on a HFD plus Pio were fed Pio at 100 mg per kg of food. Metabolic studies were performed on mice fed a HFD with or without Pio for 12 weeks. For GTTs, glucose (2.0 g per kg body weight) was administered by intraperitoneal (i.p.) injection after an overnight fast. For insulin tolerance tests, insulin (0.75 U) was administered by i.p. injection after 4 h of fasting.
CD4 1 CD25 2 T cells were activated for 48 h with anti-CD3/CD28 antibodycoated beads plus recombinant human IL-2 before retroviral transduction and cultured for 72 h after transduction. In selected experiments, 24 h after infection, transduced cells were treated with 1 mM Pio, rosiglitazone or GW1929, or with vehicle (dimethylsulphoxide) for 48 h before sorting. For T-cell analysis, cells were stained with anti-CD45, -CD3, -CD4, -CD8, -CD25 and sometimes anti-CD36, fixed, permeabilized and intracellularly stained for Foxp3 and GATA3. For intracellular lipids, cells were stained with anti-CD3, anti-CD4 and Nile red (1 mg ml 21 ). RNA from double-sorted cells was prepared for microarray analysis 2 , and hybridized to GeneChip Mouse Genome M1.0 ST arrays (Affymetrix).
